Rupee rises 8 paise to close at 86.03 against U.S. dollar
The rupee rose 8 paise to 86.03 (provisional) against the U.S. dollar on Monday (June 16, 2025) amid a strong show at the domestic equity markets, weakening dollar, and easing of global crude oil prices.
However, decline in exports, along with foreign fund outflows, capped further gains in the local unit, forex traders said.
At the interbank foreign exchange, the local unit opened at 86.16 against the greenback and traded in the range of 85.94-86.24 before closing at 86.03 (provisional), up 8 paise from its previous close.
The rupee had plummeted 59 paise to 86.11 against the U.S. dollar on Friday (June 13, 2025).
The rupee regained, 'but there was good dollar buying at lower levels as markets awaited the outcome of the continuing Iran-Israel war in the Middle East', Anil Kumar Bhansali, Head of Treasury and Executive Director, Finrex Treasury Advisors LLP, said, adding that the rupee level could be in a wider range of 85.75 to 86.50 on Tuesday (June 17, 2025).
India's exports declined 2.17% to $38.73 billion in May, while the trade deficit stood at $21.88 billion in the month, the latest government data showed on Monday (June 16, 2025).
Imports declined 1.7% year-on-year to $60.61 billion in May.
Wholesale price inflation (WPI) in the country declined to 0.39% in May as prices of food articles, manufactured products, and fuel eased, as per government data.
WPI-based inflation was 0.85% in April. It was 2.74% in May last year.
Meanwhile, in the domestic equity market, the 30-share BSE Sensex jumped 677.55 points to settle at 81,796.15 while Nifty climbed 227.90 points to 24,946.50.
The prices of Brent crude — the global oil benchmark — dipped 0.79% to 73.64 per barrel in futures trade after rising sharply over the past few days owing to the escalating Israel-Iran conflict.
The dollar index, which gauges the greenback's strength against a basket of six currencies, declined 0.20% to 97.98.
India's forex reserves increased $5.17 billion to $696.65 billion for the week ended June 6, the Reserve Bank of India said on Friday (June 13, 2025).
Foreign institutional investors (FIIs) offloaded equities worth ₹1,263.52 crore on a net basis on Friday (June 13, 2025), according to exchange data.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
20 minutes ago
- Business Standard
Higher crude oil prices, production gains positive for upstream players
Even if Iranian production is curtailed, the OPEC+ decision to ramp up production implies other supply would compensate Devangshu Datta Listen to This Article Brent crude oil prices have spiked 7 per cent (to $74 per barrel) after the war began between Israel and Iran. Iran's oil production is 3.5 million barrels per day (mmbpd) with around 2.5 mmbpd of exports. And, China is the buyer of over 80 per cent of this. The Israeli assault targeted Iranian infrastructure. There is also some chance of disruption of shipping via the Straits of Hormuz, which is a choke point for 20 per cent of global oil and gas traffic. It includes exports from Saudi Arabia, Iraq, Iran, UAE, Kuwait and Qatar. Even if Iranian production
Time of India
21 minutes ago
- Time of India
India's May trade gap narrows, exports dip 2.2%
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel New Delhi: India's goods exports declined 2.17% on-year to $38.73 billion in May while trade deficit narrowed to $21.88 billion in the month from $26.4 billion in April and $22.09 billion a year ago, official data released Monday declined 1.7% to $60.61 billion in May. Gold imports fell 12.6% in the month."Despite global policy uncertainty regarding trade and conflicts which are going on, we have done extremely well," said commerce secretary Sunil Barthwal, adding that there was a sustained fall in petrol prices which has had a dampening impact on to the US rose 16.9% in May and among sectors, electronic goods, inorganic and organic chemicals, pharma, ready-made garments, drove outbound added that India will continue with the policy of focussing on six key sectors that make up 75% of global imports. "Despite the negative forecast of WTO, India is doing much are some conflicts we are watching from the perspective of trade," he May, 13 of the 30 key sectors registered a decline in exports."The latest trade figures reflect the robust performance of India's services sector, which continues to act as a buffer against the challenges of muted global demand, geopolitical tensions, and high interest rates," said S C Ralhan, president, Federation of Indian Export Organisations (FIEO).Barthwal said both diplomatic and commercial discussions are going on with China to address issues related to Beijing's export curbs on rare earth magnets, mainly used in the auto restrictions on the export of rare earth elements and related magnets are affecting the domestic auto and white goods sectors."We are making all the efforts to see that these essential items of imports can come to India... this diplomatic and commercial communication should yield a positive result," Barthwal automobile industry has sought government support in expediting approvals from the Chinese government to import rare earth magnets used in various applications including passenger cars. "These curbs are against all the countries and are not against India only," Barthwal said, adding that the government is in talks with both the Society of Indian Automobile Manufacturers (SIAM) and the Automotive Component Manufacturers Association of India (ACMA)."We are facilitating them to have discussions with their counterparts in China and at the diplomatic level the external affairs ministry and the department of commerce also have spoken to our ambassador over there," he said the government was closely monitoring the situation arising from the Iran-Israel conflict, and a meeting with shipping lines, container firms, and other stakeholders will be held this week to assess the impact on the country overseas trade and address any issue."We are watching the situation. We are also calling a meeting (this week) of all shipping lines, the container organisations and concerned departments, and stakeholders to understand the kind of issues they are facing and how we can sort it out," he said.
Time of India
23 minutes ago
- Time of India
US pharma bets big on China to snap up potential blockbuster drugs
U.S. drugmakers are increasingly licensing drug candidates from Chinese biotech firms, with 14 such deals worth up to $18.3 billion signed in 2025 so far—up from just two in the same period last year, according to GlobalData. This surge is driven by the need to replace $200 billion worth of medicines set to lose patent protection by 2030. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads ( Originally published on Jun 16, 2025 ) U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as $80 million into multibillion-dollar June, U.S. drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies. That compares with just two such deals in the year-earlier period, according to data from GlobalData provided exclusively to increased pace is expected to continue as U.S. drugmakers look to rebuild pipelines of future products to replace $200 billion worth of medicines that will lose patent protection by the end of the decade, analysts, investors, a banker and a drug company executive told Reuters."They are finding very high-quality assets coming out of China and at prices that are much more affordable relative to perhaps the equivalent type of product that they might find in the United States," said Mizuho analyst Graig total cost of licensing agreements, including low upfront payments and subsequent larger payouts, averaged $84.8 billion in the U.S., compared with $31.3 billion in China over the past five years, according to GlobalData.A licensing agreement grants a company the rights to develop, manufacture, and commercialize another company's pharmaceutical products or technologies in exchange for future target-based, or "milestone", payments while mitigating development share of global drug development is now nearly 30%, while the U.S. share of the world's research and development has slipped 1% to about 48%, according to pharmaceutical data provider Citeline's report in companies have licensed experimental drugs to U.S. drugmakers that could be used for obesity, heart disease and cancer, reflecting abundant Chinese government investment in pharmaceutical and biotech research and small molecules, like oral drugs, have been the most commonly licensed, there has been a notable shift toward novel treatments such as targeted cancer therapies and first-in-class medicines, Jefferies analysts said in a note in May. Chinese biotechs are moving up the value chain by the day. They are... challenging their Western peers," said Macquarie Capital analyst Tony growth is happening even as the U.S. and China have wrangled over tariffs and U.S. President Donald Trump pushes a made in America has cut into traditional mergers and acquisitions, which are down 20%, with only 50 such transactions so far this year, according to data from a third of the assets that large pharmaceutical companies licensed in 2024 were from China, said Brian Gleason, head of biotech investment banking at Raymond James, who estimated such licensing deals would increase to between 40% and 50%."I think it's only accelerating," Gleason Trump administration is currently doing a national security investigation as it weighs if it will impose tariffs on the pharmaceutical one healthcare analyst said licensing deals should continue because the yet to be marketed products are not impacted by tariffs."The law that gives the president the right to impose tariffs applies to goods. It explicitly excludes intellectual property," said Tim Opler, managing director in Stifel's global healthcare May, Pfizer spent $1.25 billion upfront for the right to license an experimental cancer drug from China's 3SBio . That is the largest such deal this year and could be worth up to $6 billion in payments to 3SBio if the drug is Pharmaceuticals in June paid $80 million upfront in a potential $2 billion deal for an experimental obesity drug from China's Hansoh Pharmaceuticals.'WAKEUP CALL'By licensing a drug in development, U.S. and European drugmakers get very quick access to a molecule which would take them longer and cost more to discover or design themselves, analysts say.U.S.-based drug developer Nuvation Bio bought AnHeart Therapeutics in 2024, gaining access to the China-based company's experimental cancer drug taletrectinib, which received U.S. approval last week."We consider our presence in China not only a great avenue for R&D, but we also view it as an inside track on obtaining further assets to grow our company further and find new and better therapies to offer patients," Nuvation CEO David Hung told makes China attractive, said EY analyst Arda Ural, "a fraction of the cost and then multiples of time."Analysts have pointed to large drugmakers strategically securing rights to drugs at lower cost and running efficient early-stage trials in China to obtain important data, paving the way for global trials and potential earlier market entry."It's a little bit of a wakeup call to our industry," said Chen Yu, Managing Partner at U.S.-based healthcare investment firm TCGX.
